Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP6V1B1 | P15313 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 8/20 | 0.52 |
| ▸ | DRD3 | P35462 | 5/20 | 0.52 |
| ▸ | DRD4 | P21917 | 5/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438021 | 0.88 | DRD2 (0.56) | DRD2DRD3DRD4CYP2C9HTR2A | |
| SCHEMBL5648781 | 0.87 | DRD2 (0.51) | ATP6V1B1DRD2DRD3DRD4HTR1A | |
| SCHEMBL6582844 | 0.87 | DRD4 (0.58) | DRD2DRD3DRD4HTR1ACYP2D6 | |
| SCHEMBL6438911 | 0.87 | DRD2 (0.54) | DRD2DRD3DRD4HTR1AADRA2A | |
| SCHEMBL14341055 | 0.84 | DRD2 (0.56) | DRD2DRD3DRD4HTR1ACYP2D6 | |
| SCHEMBL14341053 | 0.83 | DRD2 (0.55) | DRD2DRD3DRD4HTR2AHTR2C | |
| SCHEMBL5648705 | 0.78 | ATP6V1B1 (0.49) | ATP6V1B1DRD2DRD3DRD4HTR1A | |
| SCHEMBL6438922 | 0.76 | PRMT5 (0.52) | ATP6V1B1DRD2DRD3DRD4ADRA2A | |
| SCHEMBL6583307 | 0.75 | ACHE (0.44) | DRD2DRD3DRD4KMT2A | |
| SCHEMBL5652239 | 0.75 | CYP2D6 (0.61) | CYP2D6CYP2C9MEN1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | FARINA CARLO (IT) | 2004-11-25 | — | — | US | claimed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | claimed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | claimed |
| EP-1212317-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GlaxoSmithKline S.p.A. (IT) | 2002-06-12 | — | — | EP | claimed |
| WO-2001002388-A1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | GLAXOSMITHKLINE S.P.A. (IT) | 2001-01-11 | — | — | WO | claimed |
| EP-1212317-B1 | INDOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF OSTEOPOROSIS AMONGST OTHER APPLICATIONS | NIKEM RESEARCH SRL (IT) | 2004-09-15 | — | — | EP | disclosed |
| US-6787550-B1 | 4-(5,6-DICHLORO-1H-INDOL-2-YL)-3-ETHOXY-N-(2,2,6,6 -TETRAMETHYLTETRAMETHYLPIPERIDIN-4-YL)-BENZAMIDE | NIKEM RESEARCH S.R.L. (IT) | 2004-09-07 | — | — | US | disclosed |
| WO-2002032916-A2 | SIXTEEN-MEMBERED MACROLIDE COMPOUNDS | KOSAN BIOSCIENCES, INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235930-A1 | Indole derivatives and their use for the treatment of osteoporosis amongst other applications | MALT1, SOST, NFATC1 | ATP6V1B1 401/4885DRD2 1893/4885DRD3 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.